id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10170 R37109 |
Blotière (Levetiracetam) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Spina bifida | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.73 [0.07;42.42] C excluded (control group) |
0/579 1/2,997 | 1 | 579 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10037 R36194 |
Blotière (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2019 | Spina bifida | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 2.63 [0.16;42.13] C | 0/579 616/1,875,733 | 616 | 579 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8998 R30564 |
Veiby (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2014 | Spina bifida | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Partial overlapping |
5.22 [0.10;264.46] C excluded (control group) |
0/114 0/593 | 0 | 114 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9000 R30569 |
Veiby (Levetiracetam) (Controls unexposed, sick), 2014 | Spina bifida | throughout pregnancy | population based cohort retrospective | unexposed, sick | Adjustment: No | 4.74 [0.24;92.40] C | 0/114 3/3,773 | 3 | 114 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9829 R35237 |
Vajda (Levetiracetam) (Controls unexposed, sick), 2013 | Spina bifida | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 2.34 [0.05;119.47] C | 0/63 0/147 | 0 | 63 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 3.19 [0.53;19.33] | 619 | 756 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Controls unexposed NOS) (Mixed indications; 2: Levetiracetam) (Controls unexposed, sick; 3: Levetiracetam) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 8998, 10170